Annovis Bio (ANVS) Gains from Investment Securities (2023 - 2026)
Annovis Bio (ANVS) posted Gains from Investment Securities of -$268000.0 for Q1 2026, down 190.54% sequentially from $296000.0 in Q4 2025, and up 51.97% YoY from -$176349.1 in Q1 2025.
Annovis Bio (ANVS) Gains from Investment Securities (2023 - 2026) Analysis & Trends
Annovis Bio has reported Gains from Investment Securities for 4 years, with the latest figure at -$268000.0 in Q1 2026.
- Quarterly Gains from Investment Securities rose 51.97% year-over-year to -$268000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$92000.0 (up 98.19% YoY) and the FY2025 annual result came in at -$142000.0, up 96.08% from the prior year.
- Gains from Investment Securities slipped to -$268000.0 in Q1 2026 per ANVS's latest filing, from $296000.0 in the prior quarter.
- Over five years, Gains from Investment Securities peaked at $4.1 million in Q2 2024 and troughed at -$11.8 million in Q4 2023.
- A 4-year average of -$2.4 million and a median of -$413000.0 in 2025 frame the typical range for Gains from Investment Securities.
- The widest YoY moves for Gains from Investment Securities: up 140.72% in 2025, down 103.45% in 2025.
- Over 4 years, Gains from Investment Securities stood at -$11.8 million in 2023, then soared by 93.86% to -$727001.0 in 2024, then surged by 140.72% to $296000.0 in 2025, then slumped by 190.54% to -$268000.0 in 2026.
- According to Business Quant data, Gains from Investment Securities over the past three periods registered -$268000.0, $296000.0, and $20000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Annovis Bio | 67.91 Mn | 67.91 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -268,000.00 |
| Mar 31, 2026 | -268,000.00 |
| Dec 31, 2025 | 296,000.00 |
| Dec 31, 2025 | 296,000.00 |
| Sep 30, 2025 | 20,000.00 |
| Sep 30, 2025 | 20,000.00 |
| Jun 30, 2025 | -140,000.00 |
| Jun 30, 2025 | -140,000.00 |
| Mar 31, 2025 | -558,000.00 |
| Mar 31, 2025 | -558,000.00 |
| Dec 31, 2024 | -727,001.00 |
| Dec 31, 2024 | -727,001.00 |
| Sep 30, 2024 | -7.86 Mn |
| Sep 30, 2024 | -7.86 Mn |
| Jun 30, 2024 | 4.06 Mn |
| Jun 30, 2024 | 4.06 Mn |
| Mar 31, 2024 | -6.70 Mn |
| Mar 31, 2024 | -6.70 Mn |
| Dec 31, 2023 | -11.84 Mn |
| Dec 31, 2023 | -11.84 Mn |